Suppr超能文献

NMR 引导的强效和选择性 EphA4 激动配体的设计。

NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.

机构信息

Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.

Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.

出版信息

J Med Chem. 2021 Aug 12;64(15):11229-11246. doi: 10.1021/acs.jmedchem.1c00608. Epub 2021 Jul 22.

Abstract

In this paper, we applied an innovative nuclear magnetic resonance (NMR)-guided screening and ligand design approach, named focused high-throughput screening by NMR (fHTS by NMR), to derive potent, low-molecular-weight ligands capable of mimicking interactions elicited by ephrin ligands on the receptor tyrosine kinase EphA4. The agents bind with nanomolar affinity, trigger receptor activation in cellular assays with motor neurons, and provide remarkable motor neuron protection from amyotrophic lateral sclerosis (ALS) patient-derived astrocytes. Structural studies on the complex between EphA4 ligand-binding domain and a most active agent provide insights into the mechanism of the agents at a molecular level. Together with preliminary in vivo pharmacology studies, the data form a strong foundation for the translation of these agents for the treatment of ALS and potentially other human diseases.

摘要

在本文中,我们应用了一种创新的基于核磁共振(NMR)的筛选和配体设计方法,命名为基于 NMR 的聚焦高通量筛选(fHTS by NMR),以获得能够模拟受体酪氨酸激酶 EphA4 上的 Ephrin 配体所引发的相互作用的、有效且低分子量的配体。这些化合物具有纳摩尔亲和力,在针对运动神经元的细胞测定中触发受体激活,并能显著保护运动神经元免受肌萎缩侧索硬化症(ALS)患者衍生的星形胶质细胞的侵害。EphA4 配体结合域与最活跃的化合物之间的结构研究为这些化合物在分子水平上的作用机制提供了深入的了解。与初步的体内药理学研究一起,这些数据为将这些化合物用于治疗 ALS 以及可能的其他人类疾病奠定了坚实的基础。

相似文献

1
NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.
J Med Chem. 2021 Aug 12;64(15):11229-11246. doi: 10.1021/acs.jmedchem.1c00608. Epub 2021 Jul 22.
2
Potent and Selective EphA4 Agonists for the Treatment of ALS.
Cell Chem Biol. 2017 Mar 16;24(3):293-305. doi: 10.1016/j.chembiol.2017.01.006. Epub 2017 Feb 9.
3
Dynamic principle for designing antagonistic/agonistic molecules for EphA4 receptor, the only known ALS modifier.
ACS Chem Biol. 2015 Feb 20;10(2):372-8. doi: 10.1021/cb500413n. Epub 2014 Oct 24.
5
Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity.
J Biol Chem. 2010 Jan 1;285(1):644-54. doi: 10.1074/jbc.M109.064824. Epub 2009 Oct 29.
6
7
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
Acta Neuropathol Commun. 2019 Jul 12;7(1):114. doi: 10.1186/s40478-019-0759-6.
9
EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes.
iScience. 2022 Aug 5;25(9):104877. doi: 10.1016/j.isci.2022.104877. eCollection 2022 Sep 16.
10
Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
ACS Chem Biol. 2014 Dec 19;9(12):2787-95. doi: 10.1021/cb500677x. Epub 2014 Oct 14.

引用本文的文献

1
Constrained β-Hairpins Targeting the EphA4 Ligand Binding Domain.
J Med Chem. 2024 Dec 26;67(24):22245-22253. doi: 10.1021/acs.jmedchem.4c02286. Epub 2024 Dec 10.
3
Mixture-Based Screening of Focused Combinatorial Libraries by NMR: Application to the Antiapoptotic Protein hMcl-1.
J Med Chem. 2023 Jul 27;66(14):10108-10118. doi: 10.1021/acs.jmedchem.3c01073. Epub 2023 Jul 18.
4
EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes.
iScience. 2022 Aug 5;25(9):104877. doi: 10.1016/j.isci.2022.104877. eCollection 2022 Sep 16.

本文引用的文献

1
The Expression of the Cancer-Associated lncRNA Is Modulated by EphrinA5-Induced Signaling.
Int J Mol Sci. 2021 Jan 29;22(3):1332. doi: 10.3390/ijms22031332.
2
Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.
J Med Chem. 2020 Nov 12;63(21):12911-12920. doi: 10.1021/acs.jmedchem.0c01285. Epub 2020 Oct 27.
4
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
Acta Neuropathol Commun. 2019 Jul 12;7(1):114. doi: 10.1186/s40478-019-0759-6.
6
Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach.
J Med Chem. 2018 Jul 26;61(14):6350-6363. doi: 10.1021/acs.jmedchem.8b00810. Epub 2018 Jul 9.
7
Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.
Curr Opin Chem Biol. 2018 Jun;44:75-86. doi: 10.1016/j.cbpa.2018.06.004. Epub 2018 Jun 13.
8
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.
ACS Med Chem Lett. 2018 Jan 17;9(2):137-142. doi: 10.1021/acsmedchemlett.7b00483. eCollection 2018 Feb 8.
9
Enthalpy-Based Screening of Focused Combinatorial Libraries for the Identification of Potent and Selective Ligands.
ACS Chem Biol. 2017 Dec 15;12(12):2981-2989. doi: 10.1021/acschembio.7b00717. Epub 2017 Nov 2.
10
Potent and Selective EphA4 Agonists for the Treatment of ALS.
Cell Chem Biol. 2017 Mar 16;24(3):293-305. doi: 10.1016/j.chembiol.2017.01.006. Epub 2017 Feb 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验